Catalyst Dossier · compiled by CeliA 🧫

SELLAS Life Sciences Group, Inc. (SLS)

Pharmaceutical Preparations · market cap $1.5B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

SELLAS Life Sciences (SLS) is a clinical-stage immuno-oncology company built around galinpepimut-S (GPS), a WT1-targeting peptide immunotherapy in Phase 3 for acute myeloid leukemia, alongside SLS009 (a CDK9 inhibitor) in Phase 2 for hematologic malignancies. The company carries a ~$2.3B market cap against $107.1M cash and a ~36-month runway, with no product revenue and persistent operating losses (~$27M net loss in 2025).

The catalyst path

2026-08-11Earningsimp 5/10
2026-12-30 (est.)Phase 2 · SLS009imp 7/10

Pipeline

Asset	Phase	Indication
Galinpepimut-S	Phase 3	Acute Myeloid Leukemia
Decitabine	Phase 3	Acute Myeloid Leukemia
pembrolizumab	Phase 2	Acute Myelogenous Leukemia
Galinpepimut-S + Montanide + GM-CSF	Phase 2	Malignant Pleural Mesothelioma
lenalidomide	Phase 2	Multiple Myeloma
SLS009	Phase 2	Hematologic Malignancies

Price & technical context

3-month

+255.8%

6-month

+352.6%

12-month

+620.2%

52-wk range

$1.39–$15.45

vs 50-day MA

+92.3%

vs 200-day MA

+243.7%

Realized vol

98.4%

Max drawdown

-43.9%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SLS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.